LOMBARDI, GAETANO
 Distribuzione geografica
Continente #
NA - Nord America 7.209
EU - Europa 3.743
AS - Asia 1.415
AF - Africa 129
SA - Sud America 36
Continente sconosciuto - Info sul continente non disponibili 16
OC - Oceania 5
Totale 12.553
Nazione #
US - Stati Uniti d'America 7.087
CN - Cina 1.217
IT - Italia 620
DE - Germania 589
SE - Svezia 536
FI - Finlandia 505
IE - Irlanda 484
NL - Olanda 455
UA - Ucraina 294
GB - Regno Unito 139
CI - Costa d'Avorio 118
CA - Canada 113
TR - Turchia 56
IN - India 55
FR - Francia 45
IR - Iran 23
BE - Belgio 17
EU - Europa 16
VN - Vietnam 16
SG - Singapore 13
ES - Italia 11
BR - Brasile 10
CO - Colombia 9
JP - Giappone 8
MX - Messico 8
CH - Svizzera 7
AR - Argentina 6
CL - Cile 6
EG - Egitto 6
PL - Polonia 5
RO - Romania 5
TH - Thailandia 5
AT - Austria 4
KR - Corea 4
NO - Norvegia 4
AU - Australia 3
DK - Danimarca 3
EC - Ecuador 3
GR - Grecia 3
HR - Croazia 3
HU - Ungheria 3
IQ - Iraq 3
MY - Malesia 3
RU - Federazione Russa 3
CZ - Repubblica Ceca 2
GE - Georgia 2
HK - Hong Kong 2
IL - Israele 2
LV - Lettonia 2
NG - Nigeria 2
NZ - Nuova Zelanda 2
PE - Perù 2
PT - Portogallo 2
SK - Slovacchia (Repubblica Slovacca) 2
TW - Taiwan 2
DZ - Algeria 1
ID - Indonesia 1
KH - Cambogia 1
LK - Sri Lanka 1
NP - Nepal 1
PR - Porto Rico 1
TN - Tunisia 1
ZA - Sudafrica 1
Totale 12.553
Città #
Chandler 1.523
Jacksonville 664
Millbury 597
Princeton 510
Amsterdam 429
Nanjing 420
Wilmington 331
Ashburn 268
Naples 209
Beijing 193
Woodbridge 156
Nanchang 149
Boston 146
Ottawa 99
Norwalk 94
Shenyang 77
Ann Arbor 63
Hebei 62
Napoli 61
Jiaxing 60
Falls Church 56
Tianjin 52
Houston 50
Kunming 43
Boardman 40
Changsha 39
Kronberg 39
Redwood City 34
Seattle 30
Indiana 29
Dublin 26
Washington 26
San Mateo 24
Pune 21
Redmond 20
Lanzhou 19
Ardabil 18
Augusta 18
Los Angeles 17
Des Moines 16
Dong Ket 16
Jinan 16
Rome 15
Milan 14
New York 14
Yellow Springs 13
Dearborn 12
San Francisco 12
Shanghai 12
Tappahannock 12
Changchun 11
Hangzhou 11
Istanbul 11
Toronto 11
Leawood 10
Ningbo 9
Duncan 8
Singapore 8
Orange 7
Zhengzhou 7
Casoria 6
Courcelles 6
Paris 6
Casalbore 5
Fremont 5
Monfalcone 5
Simi Valley 5
Aracaju 4
Bangalore 4
Frankfurt am Main 4
Guangzhou 4
Monmouth Junction 4
Oslo 4
San Prisco 4
Taizhou 4
Torino 4
Venezia 4
Warsaw 4
Basel 3
Buenos Aires 3
Chatsworth 3
Cleveland 3
Dogliani 3
Fuzhou 3
Heidelberg 3
Lappeenranta 3
Madrid 3
Pittsburgh 3
San Diego 3
Vellore 3
Vollezele 3
Woodstock 3
Albersweiler 2
Ansbach 2
Athens 2
Avellino 2
Baghdad 2
Bagheria 2
Baiut 2
Bologna 2
Totale 7.097
Nome #
Systemic complications of acromegaly: epidemiology, pathogenesis, and management 394
Circulating insulin-like growth factor-I levels are correlated with the atherosclerotic profile in healthy subjects independently of age 78
Short-term effects of growth hormone (GH) treatment or deprivation on cardiovascular risk parameters and intima-media thickness at carotid arteries in patients with severe GH deficiency 69
A protein family immunorelated to a sperm-binding protein and its regulation in human semen. 67
Antipituitary antibodies in idiopathic hyperprolactinemic patients 63
Efficacy and safety of radiofrequency thermal ablation in the treatment of thyroid nodules with pressure symptoms in elderly patients. 62
Lack of electrocardiographic changes in women with polycystic ovary syndrome. 60
Role of dehydroepiandrosterone sulfate levels on body composition after laparoscopic adjustable gastric banding in pre-menopausal morbidly obese women. 60
Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly 58
Effects of sex steroids on bone in women with subclinical or overt endogenous hypercortisolism 57
Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients 56
Weekly clodronate treatment prevents bone loss and vertebral fractures in womenwith subclinical Cushing's syndrome. 56
Thyroid function and morphology after a successful kidney transplantation. 55
GH INSUFFICIENCY IN OBESE PATIENTS. 55
Subclinical hyperthyroidism: clinical features and treatment options. 54
Combined therapy of somatostatin analogues and dopamine agonists in the treatment of pituitary tumours 54
CORRELATION BETWEEN SEMINAL CARNITINE AND FUNCTIONAL CHARACTERISTICS IN MEN WITH SEMEN DYSFUNCTION OF VARIOUS ORIGINS. 54
Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance 54
Sulfur amino acids in Cushing's disease: insight in homocysteine and taurine levels in patients with active and cured disease 53
Prolactin and prostate hypertrophy: a pilot observational, prospective, case-control study in men with prolactinoma 52
Homocysteine levels and C677T polymorphism of methylenetetrahydrofolate reductase in women with polycystic ovary syndrome 52
Correlation between Seminal Carnitine and Functional Spermatozoal Characteristics in Men with Semen Dysfunction of Various Origins 51
The treatment with growth hormone receptor antagonist in acromegaly: effect on vascular structure and function in patients resistant to somatostatin analogues. 51
A retrospective analysis on biochemical parameters, cardiovascular risk and cardiomyopathy in elderly acromegalic patients 50
Orbital scintigraphy with [111In-diethylenetriamine pentaacetic acid-D-phe1]-octreotide predicts the clinical response to corticosteroid therapy in patients with Graves' ophthalmopathy. 49
Recombinant thyrotropin-induced orbital uptake of [111In-diethylenetriamine-pentacetic acid-D-Phe1]octreotide in a patient with inactive Graves' ophthalmopathy. 49
Cardiopulmonary impairment in young women with polycystic ovary syndrome 49
Increased prevalence of thyroid autoimmunity and hypothyroidism in patients with glycogen storage disease type I 48
31. SIX MONTHS OF TREATMENT WITH CABERGOLINE RESTORES SEXUAL POTENCY IN HYPERPROLACTINEMIC MALES. AN OPEN LONGITUDINAL STUDY MONITORING NOCTURNAL PENILE TUMESCENCE. 48
Overexpression of the phosphoprotein enriched in diabetes gene product (Ped/pea-15) in women with polycystic ovary syndrome. 48
Subtle alterations of cardiac performance in children with growth hormone deficiency: results of a two-year prospective, case-control study. 48
Differences of myocardial systolic deformation and correlates of diastolic function in competitive rowers and young hypertensives: a speckle-tracking echocardiography study. 48
Epidemiology, diagnosis, and treatment of male hypogonadotropic hypogonadism. 48
Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly. 47
Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine 47
Effects of neridronate treatment in elderly women with osteoporosis 46
Advances in the treatment of prolactinomas 46
Bone demineralization and vertebral fractures in endogenous cortisol excess: role of disease etiology and gonadal status 46
L'ESPOSIZIONE AMBIENTALE è UN FATTORE DI RISCHIO MASCHILE? 45
The natural history of partial growth hormone deficiency in adults: a prospective study on the cardiovascular risk and atherosclerosis. 45
Effects of short-term treatment with orlistat on growth hormone/insulin-like growth factor-I axis in obese post-menopausal women. 45
The association of fasting insulin concentrations and colonic neoplasms in acromegaly: a colonoscopy-based study in 210 patients 44
Endocrine dysfunction in patients with Fabry disease 44
SOM230, a new somatostatin analogue, is highly effective in the therapy of growth hormone/prolactin-secreting pituitary adenomas. 44
First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial. 44
Predictive value of pentagastrin test for preoperative differential diagnosis between C-cell hyperplasia and medullary thyroid carcinoma in patients with moderately elevated basal calcitonin levels. 44
Epidemiology of non-gastroenteropancreatic (neuro)endocrine tumours. 43
Hypertension in acromegaly and in the normal population: prevalence and determinants 43
Different degrees of GH deficiency evidenced by GHRH+arginine test and IGF-I levels in adults with pituritary disease 42
Identification and preliminary characterization of a sperm-binding protein in normal human semen 42
The treatment with cabergoline for 24 month normalizes the quality of seminal fluid in hyperprolactinaemic males. 42
Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly 42
Alpha-melanocyte-stimulating hormone is present in the inferior petrosal sinuses in patients with Cushing's disease. 42
The Mia/Cd-rap gene expression is downregulated by the high-mobility group A proteins in mouse pituitary adenomas. 41
ANP, AVP, AND PITUITARY-THYROID AXIS IN PATIENTS WITH CONGESTIVE HEART FAILURE AND ACUTE RESPIRATORY FAILURE. 41
Role of IGF-I on PTH effects on bone. 41
A decrease of calcitonin serum concentrations less than 50 percent 30 minutes after thyroid surgery suggests incomplete C-cell tumor tissue removal. 41
The cut-off limits of the GH response to GH-releasing hormone-arginine test related to body mass index. 40
Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males 40
Acute and chronic effects of human recombinant GH (hrGH) on adrenal steroidogenesis in children affected with isolated GH deficiency (IGHD) 40
Acromegalic axial arthropathy: a clinical case-control study 39
Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study 39
Cushing's syndrome: aftermath of the cure. 39
Common carotid intima-media thickness in growth hormone (GH)-deficient adolescents: a prospective study after GH withdrawal and restarting GH replacement. 38
Growth hormone excess with onset in adolescence: clinical appearance and long-term treatment outcome 38
Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission 38
Complete disappearance of a GH-secreting pituitary macroadenoma in a patient with acromegaly: effect of treatment with lanreotide Autogel and consequence of treatment withdrawal. 38
Adjuvant Growth Hormone therapy in severely obese women with Growth Hormone Deficiency after Laparoscopic Adjustable Silicone Gastric Banding. 38
Appropriate use of stimulation tests and insulin-like growth factor-I in obesity 37
Cushing's syndrome 37
Octreotide-LAR vs lanreotide-SR as first-line therapy for acromegaly: A retrospective, comparative, head-to-head study 37
Two mutations of BRCA2 gene at exon and splicing site in a woman who underwent oncogenetic counseling 37
Beneficial effects of a three-month structured exercise training program on cardiopulmonary functional capacity in young women with polycystic ovary syndrome 37
Pegvisomant in acromegaly: why, when, how 36
Human seminal plasma proteins: identification and preliminary characterization of a sperm coating antigen (h-SCA) protein in physiological and pathological conditions. 36
Growth hormone status in morbidly obese subjects and correlation with body composition 36
Short-term suppression of GH and IGF-I levels improves gonadal function and sperm parameters in men with acromegaly 36
Corticotropin-releasing hormone administration increases alpha-melanocyte-stimulating hormone levels in the inferior petrosal sinuses in a subset of patients with Cushing's disease 36
A pilot study for neonatal screening of congenital adrenal hyperplasia due to 21-hydroxylase and 11-beta-hydroxylase deficiency in Campania region 36
Correlation of scintigraphic results using 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas 36
Prevalence of the metabolic syndrome in moderately-severely obese subjects with and without growth hormone deficiency. 36
Changes in insulin levels following 6-month treatment with recombinant human growth hormone in growth hormone-deficient adults. 36
Growth hormone nadir during oral glucose load depends on waist circumference, gender and age: normative data in 231 healthy subjects. 36
Lack of change in insulin levels as a biological marker of PAI-1 lowering in GH-deficient adults on r-HGH replacement therapy. 36
Clinical and prognostic implications of the genetic diagnosis of hereditary NET syndromes in asymptomatic patients 36
Relationship between metabolic syndrome and multinodular non-toxic goiter in an inpatient population from a geographic area with moderate iodine deficiency 36
Acromegaly 35
PRL secreting adenomas in male patients 35
An evaluation of patients with hyperprolactinemia: have dynamic tests had their day? 35
Cardiac structural and functional abnormalities in adult patients with growth hormone deficiency 35
A reappraisal of diagnosing GH deficiency in adults: role of gender, age, waist circumference, and body mass index. 35
Cardiovascular disease in Cushing's syndrome: heart versus vasculature. 35
Effects of initial therapy for five years with somatostatin analogs foracromegaly on growth hormone and insulin-like growth factor-I levels, tumorshrinkage, and cardiovascular disease: a prospective study. 35
Limitations of Chromogranin A in clinical practice. 35
Thyroid function in Fabry disease before and after enzyme replacement therapy. 35
Antiproliferative and proapoptotic effects of raloxifene on uterine leiomyomas in postmenopausal women 35
Somatostatin analogs in treatment of non-growth hormone-secreting pituitary adenomas 34
Chronic treatment with CV 205-502 restores the gonadal function in hyperprolactinemic males 34
Dose reduction and discontinuation of alendronate in postmenopausal osteoporotic women who were receiving estrogen therapy 34
Metabolic and cardiovascular consequences of polycystic ovary syndrome 34
Totale 4.763
Categoria #
all - tutte 58.712
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 58.712


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201971 0 0 0 0 0 0 0 0 0 0 2 69
2019/20201.474 577 31 65 4 70 7 10 8 7 89 180 426
2020/20211.219 22 62 151 72 66 286 85 28 122 66 198 61
2021/20223.273 55 22 18 39 83 331 44 109 507 258 591 1.216
2022/20233.422 572 318 114 292 403 341 18 264 458 444 154 44
2023/20241.452 91 354 322 145 75 153 34 219 17 36 6 0
Totale 12.990